Artificial intelligence systems require consistent monitoring and staffing to put in place and to keep them working well.

Adding atezolizumab to adjuvant chemotherapy does not improve outcomes in patients with stage II-III TNBC, phase 3 data suggest.

Tislelizumab plus low-dose nab-paclitaxel “demonstrated enduring efficacy while maintaining a manageable safety profile,” according to researchers.